Detailed characteristics of patients with recurrent stroke
| Group/Age (y)/Sex | Previous stroke | Microbleeds, n | WMH, Grade | Antiplatelet Therapy | Hyper-tension | Diabetes Mellitus | Hypercho-lesterolemia | Recurrent Stroke |
|---|---|---|---|---|---|---|---|---|
| A/84/F | Lacunar infarction | 0 | 2 | Cilostazol | (+) | (−) | (−) | Lacunar infarction |
| A/71/M | Lacunar infarction | 0 | 2 | Ticlopidine | (+) | (−) | (+) | Lacunar infarction |
| A/78/F | Atherothrombotic infarction | 0 | 2 | Ticlopidine | (−) | (−) | (+) | Atherothrombotic infarction |
| A/87/F | Lacunar infarction | 0 | 2 | Aspirin | (+) | (−) | (−) | Lacunar infarction |
| A/74/F | Lacunar infarction | 0 | 2 | Aspirin | (−) | (−) | (−) | Lacunar infarction |
| A/85/F | Lacunar infarction | 0 | 3 | Cilostrazol | (+) | (−) | (−) | Lacunar infarction |
| B/70/M | Atherothrombotic infarction | 3 | 3 | Ticlopidine | (+) | (−) | (+) | Atherothrombotic infarction |
| B/57/M | Intracerebral hemorrhage | 19 | 2 | (−) | (+) | (−) | (−) | Lacunar infarction |
| B/76/F | Lacunar infarction | 2 | 2 | Cilostazol | (+) | (−) | (+) | Lacunar infarction |
| B/66/M | Lacunar infarction | 1 | 2 | Aspirin | (+) | (+) | (+) | Lacunar infarction |
| B/55/M | Lacunar infarction | 2 | 2 | Cilostazol | (−) | (−) | (−) | Lacunar infarction |
| B/69/M | Lacunar infarction | 13 | 3 | Aspirin | (+) | (−) | (−) | Intracerebral hemorrhage |
| C/54/M | Lacunar infarction | 0 | 1 | Cilostazol | (+) | (+) | (−) | Lacunar infarction |
| C/61/F | Intracerebral hemorrhage | 0 | 1 | Aspirin + ticlopidine | (+) | (+) | (−) | Lacunar infarction |
| C/61/F | Atherothrombotic infarction | 0 | 1 | Aspirin + ticlopidine | (+) | (−) | (−) | Lacunar infarction |
| C/57/F | Lacunar infarction | 0 | 0 | Aspirin | (−) | (+) | (−) | Atherothrombotic infarction |
| C/54/M | Lacunar infarction | 0 | 1 | Aspirin | (−) | (+) | (−) | Lacunar infarction |
| C/74/M | Lacunar infarction | 0 | 1 | Aspirin | (−) | (+) | (−) | Intracerebral hemorrhage |
| D/77/M | Lacunar infarction | 13 | 1 | Aspirin | (−) | (−) | (−) | Intracerebral hemorrhage |
| D/70/M | Lacunar infarction | 28 | 1 | Aspirin | (+) | (−) | (+) | Intracerebral hemorrhage |
| D/73/M | Atherothrombotic infarction | 1 | 1 | Aspirin | (+) | (−) | (−) | Intracerebral hemorrhage |
| D/80/M | Atherothrombotic infarction | 11 | 0 | Aspirin | (+) | (−) | (−) | Intracerebral hemorrhage |
| D/82/M | Intracerebral hemorrhage | 2 | 1 | (−) | (−) | (−) | (−) | Intracerebral hemorrhage |
| D/51/M | Intracerebral hemorrhage | 2 | 0 | (−) | (+) | (−) | (−) | Intracerebral hemorrhage |
| D/53/F | Intracerebral hemorrhage | 12 | 1 | (−) | (+) | (−) | (−) | Intracerebral hemorrhage |
| D/55/M | Intracerebral hemorrhage | 16 | 1 | (−) | (+) | (−) | (−) | Intracerebral hemorrhage |
Note:— Group A, patients with advanced white matter hyperintensity (WMH) but without microbleeds; group B, patients with coexistence of microbleeds and advanced WMH; group C, patients without either microbleeds or advanced WMH; group D, patients with microbleeds but without advanced WMH. Present is indicated by (+) and absent indicated by (−).